Evidence map›Paper›PMID 16267634›Full record

Trial reportEuropean archives of psychiatry and clinical neuroscience2005

Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms.

Michael Riedel, Norbert Müller, Martin Strassnig, Ilja Spellmann, Rolf R Engel, Richard Musil, Sandra Dehning, Anette Douhet, Markus J Schwarz, Hans-Jürgen Möller

Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European archives of psychiatry and clinical neuroscience, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00817648 (A 6-Week, Multicenter, Rater-blind, Randomized, Risperidone-controlled Study to Evaluate the Efficacy and Safety of Seroquel), which is not on this map. Cited by 25 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 6 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00817648 phase4completednot on this mapstarted 2008, after this paper: background citation

A 6-Week, Multicenter, Rater-blind, Randomized, Risperidone-controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia

TypeinterventionalSponsorShanghai Mental Health CenterRan2008 to 2010Enrolled120ConditionsSchizophreniaArmsQuetiapine, risperidone
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 6 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. EPA guidance on assessment of negative symptoms in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2021
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2013
    Pooled it
  5. Risperidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2011
    Pooled it
  6. Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2010
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Michael RiedelLudwig-Maximilians-University of Munich, Dept. of Psychiatry and Psychotherapy, Nussbaumstrasse 7, 80336, Munich, Germany. riedel@med.uni-muenchen.de
Norbert Müller
Martin Strassnig
Ilja Spellmann
Rolf R Engel
Richard Musil
Sandra Dehning
Anette Douhet
Markus J Schwarz
Hans-Jürgen Möller
Ludwig-Maximilians-Universität München · DEUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atypical antipsychotics are generally thought to be more effective than conventional agents in treating the negative symptoms of schizophrenia; however, there have been few direct comparisons among atypicals. We therefore investigated risperidone and quetiapine with respect to their efficacy against negative symptoms in a 12-week,double-blind, comparative pilot study involving 44 patients with schizophrenia with predominantly negative symptoms, as defined by Positive and Negative Syndrome Scale (PANSS) scores. Other efficacy measures included the Scale for the Assessment of Negative Symptoms (SANS) and the Clinical Global Impression (CGI) rating scale. Antipsychotic tolerability was assessed using the Simpson-Angus Scale (SAS) and various laboratory measures. Mean doses were 589.7 mg/ day quetiapine and 4.9 mg/day risperidone (observed cases). Both antipsychotics produced significant decreases in PANSS total, positive and negative scores, and SANS scores. Patients receiving risperidone were significantly more likely to experience extrapyramidal symptoms (EPS) [p <0.05], or to require anticholinergic medication (p <0.05), and had significantly higher prolactin levels (p <0.001) than quetiapine-treated patients. In conclusion, there is no significant difference in efficacy between quetiapine and risperidone in alleviating the negative symptoms of schizophrenia. Quetiapine is also well tolerated, with a lower incidence of EPS and prolactin increase than risperidone.

Indexed as

Schizophrenic PsychologyAdultAntipsychotic AgentsDibenzothiazepinesDouble-Blind MethodFemaleHumansMaleMiddle AgedPilot ProjectsPsychiatric Status Rating ScalesQuetiapine FumarateRisperidoneSchizophreniaAntipsychotic AgentsDibenzothiazepinesQuetiapine FumarateRisperidone

Identifiers

PMID16267634
OpenAlexW1988482389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.